ab 17 March 2026 Global Research China Medtech Marketing book Equities China Healthcare Jun Deng Analyst jun.deng@ubs.com +852-3712 2103 Chen Chen, PhD Analyst S1460520100001 chen-zb.chen@ubs.com +86-10-5832 8201 Henry Liu, CFA Analyst S1460520110002 henry-za.liu@ubs.com +86-105-832 8509 Liz Han, CFA Analyst liz.han@ubs.com +852-2971 6106 David Guo, PhD Analyst S1460524040001 david-za.guo@ubs.com +86-10-5832 8010 Emma Ma, CFA Associate S1460124070003 emma-mc.ma@ubs.com +86-21-3866 8981 This report has been ...

Company Overview - Snap-on Incorporated, based in Kenosha, Wisconsin, manufactures and markets tools, equipment, diagnostics, and repair information systems for professional users globally, with a market capitalization of $18.8 billion [1]. Market Position - Snap-on fits into the "large-cap stocks" category, reflecting its substantial size and influence in the tools and accessories industry [2]. Stock Performance - The stock reached a 52-week high of $390.13 on February 12 and has since declined by 7.2%. Over the past three months, the stock rose by 4.6%, underperforming the State Street Industrials Select Sector SPDR ETF's (XLI) 5.2% increase [3]. - Over the past 52 weeks, Snap-on's shares increased by 9.9%, but this was still below XLI's 22.7% rise during the same period [6]. Earnings Report - On February 5, Snap-on released its Q4 2025 earnings, reporting net sales of $1.2 billion, a 2.8% increase from the previous year, and adjusted EPS of $4.94, both surpassing estimates. However, the stock dropped by 3.2% following the announcement [7]. Investor Sentiment - Despite the earnings report, investor confidence has been declining due to disappointing organic revenue growth and flat EPS over the past two years. There are concerns about diminishing returns on capital [8]. - Compared to its peer, RBC Bearings Incorporated, Snap-on has underperformed, with RBC's stock surging by 63.3% over the past 52 weeks. The sentiment on Snap-on remains moderately optimistic, with a consensus rating of "Moderate Buy" among analysts and a mean price target of $376.86, indicating a 4.1% upside potential from current levels [9].

Company Overview - Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, and repair information for professional users in various sectors including vehicle repair, aerospace, military, natural resources, and manufacturing [2][3] - The company was founded in 1920 and is headquartered in Kenosha, Wisconsin [2][3] - Snap-on generated sales of $4.7 billion in 2025 and is recognized as an S&P 500 company [2] Upcoming Events - The Chairman and CEO Nick Pinchuk is scheduled to present at the 38th Annual Roth Conference in California on March 23, 2026, at 9:30 a.m. Pacific [1][4] - A live audio webcast of the presentation will be available on the Investor Events page of the Snap-on website, with an archived replay accessible for approximately 90 days [2] Financial Information - Snap-on declared a quarterly common stock dividend of $2.44 per share, payable on March 10, 2026 [6] - The company reported diluted EPS of $4.94 for the fourth quarter of 2025 [7]

Core Viewpoint - Agilent Technologies, Inc. has experienced fluctuating stock performance post-COVID, with its historical growth trajectory disrupted as the life sciences industry stabilized after the pandemic [3]. Group 1: Company Overview - Agilent Technologies provides instruments, software, and services for life sciences, diagnostics, and chemical analysis, including chromatography, spectroscopy, genomics, and laboratory automation solutions [3]. - The company is likened to Danaher in its role as a supplier to the life sciences sector, indicating a strong position within the industry [1]. Group 2: Stock Performance - Prior to the COVID-19 pandemic, Agilent's stock performance was characterized as a "thing of beauty," indicating strong growth and investor confidence [3]. - During the pandemic, Agilent's stock saw significant gains, but post-pandemic, the stock has faced volatility as the demand for new equipment from life sciences companies diminished [3]. Group 3: Market Context - The life sciences industry, including Agilent, has faced challenges as companies have sufficient equipment, leading to a prolonged period of underperformance for the sector [3].

Core Insights - Siemens Healthineers AG is a leading global medical technology company specializing in imaging, diagnostics, and advanced therapies, competing with major players like GE Healthcare and Philips [1] Financial Performance - On February 5, 2026, Siemens Healthineers reported earnings per share of $0.28, surpassing the estimated $0.27, and revenue of approximately $6.37 billion, exceeding the estimated $5.29 billion [2][6] - The strong financial performance is attributed to robust margin performance in its core imaging and cancer-care units [2] Market Valuation - The company's price-to-earnings (P/E) ratio is approximately 43.17, indicating high investor confidence in future growth prospects [3][6] - The price-to-sales ratio stands at about 3.97, suggesting the market values the company at nearly four times its annual sales [4] - The enterprise value to sales ratio is approximately 4.61, reflecting the company's total valuation relative to its sales [4] Operational Metrics - The enterprise value to operating cash flow ratio is around 34.71, indicating the company's valuation in relation to its cash flow from operations [5] - The earnings yield is approximately 2.32%, providing insight into the return on investment [5] - Siemens Healthineers has a debt-to-equity ratio of about 0.83 and a current ratio of approximately 1.11, demonstrating a moderate level of debt and good short-term financial health [5]

Core Viewpoint - Zoetis Inc. is experiencing near-term uncertainty but maintains long-term appeal due to its diverse product pipeline and potential blockbuster candidates [2][3][4]. Group 1: Analyst Downgrade and Market Sentiment - Piper Sandler downgraded Zoetis from Overweight to Neutral and reduced its price target from $190 to $135, citing uncertainty in the near term [2]. - The firm expressed concerns about the current consumer spending environment and its impact on Zoetis' planned product launches in 2026 [3]. Group 2: Product Pipeline and Innovation - Zoetis is described as being in an "innovation lull," with a potential air pocket lasting one to two years, which raises questions about its near-term growth [3]. - The company highlighted a robust pipeline during its Innovation Webcast, featuring 12 candidates with blockbuster potential across various therapeutic areas, including chronic kidney disease and oncology [4]. - Zoetis is also focusing on next-generation treatments in established franchises such as osteoarthritis pain and dermatology, indicating a balanced strategy of geographic expansion and lifecycle extensions [5]. Group 3: Company Overview - Zoetis Inc. is a global leader in animal health, dedicated to developing and commercializing a wide range of products, including medicines, vaccines, diagnostics, and precision health tools for animals [6].

Core Insights - Snap-on Incorporated (SNA) is making significant progress on its strategic priorities, leveraging its strong brand, differentiated business model, and robust customer relationships [1][5] Operational Efficiency - The company's focus on the Rapid Continuous Improvement (RCI) process is enhancing operational efficiency, driving productivity gains, and supporting cost control, which reinforces margin resilience [2][8] - RCI initiatives aim to improve organizational efficiency, reduce costs, and drive sales and margin expansion through ongoing productivity gains and process improvements [2] Franchise Network and Market Presence - Snap-on is strengthening its franchise network and deepening relationships with repair shop owners, while expanding its presence in critical industries across emerging markets [3] - The company offers a portfolio of premium hand tools, diagnostics, and specialty torque products, supported by continuous innovation and a proprietary database that enhances productivity for customers [3] Market Outlook - Snap-on expects the vehicle repair market to remain resilient, supported by innovative tool offerings and a comprehensive database [4] - Recent launches of new hand tools and growth in torque products, along with increased activity in aviation and general industrial markets, are encouraging [4] Long-term Positioning - Snap-on is well-positioned for sustainable growth, supported by strong execution and a resilient business model, with consistent cash generation and a focus on operational excellence [5] - Management anticipates continued progress by leveraging capabilities in automotive repair and expanding its customer base across geographies and critical industries [6] Financial Projections - The Zacks Consensus Estimate for SNA's 2026 sales and earnings per share (EPS) indicates a rise of 3.6% and 5.7%, respectively, year over year [9]

Core Insights - Abbott Laboratories (ABT) is valued at a market cap of $217 billion and operates in the healthcare sector, focusing on medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals [1] Financial Performance - Analysts expect ABT to report a profit of $1.50 per share for fiscal Q4 2025, reflecting an 11.9% increase from $1.34 per share in the same quarter last year [2] - For the current fiscal year ending in December, ABT is projected to report a profit of $5.15 per share, up 10.3% from $4.67 per share in fiscal 2024, with an expected EPS growth of 9.9% year-over-year to $5.66 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, ABT shares have gained 8.8%, underperforming the S&P 500 Index's 14.8% return and the State Street Health Care Select Sector SPDR ETF's 11.8% increase [4] - On October 15, ABT shares fell by 2.9% following mixed Q3 earnings results, with net sales increasing 6.9% year-over-year to $11.4 billion but missing consensus estimates due to a decline in the diagnostic products segment [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for ABT, with 19 out of 27 analysts recommending "Strong Buy," two suggesting "Moderate Buy," and six indicating "Hold." The mean price target for ABT is $146.69, suggesting a 17.5% potential upside from current levels [6]

Core Viewpoint - Thermo Fisher Scientific Inc. (TMO) is recognized as one of the best stocks to buy in the S&P 500, with a consensus Strong Buy rating from analysts and a one-year price target indicating a potential upside of 12% [1]. Analyst Updates - Wells Fargo raised its price target for TMO to $675 from $635, citing improved clarity on U.S. pharmaceutical policies and positive growth projections [2]. - Citigroup upgraded TMO's rating to Buy from Neutral and increased its price target to $660 from $580, driven by favorable trends in onshoring and pharmaceutical spending [3]. Company Overview - Thermo Fisher Scientific is a leading provider of life sciences solutions, laboratory products, diagnostics, analytical instruments, and biopharma services, with an 8% gain year-to-date in 2025 [4].

Market Overview - The S&P 500 index fell 1.16% to close at 6,721.43, marking the fourth consecutive day of decline due to an ongoing AI infrastructure selloff [1] - Despite the recent downturn, the S&P 500 is up 14.28% year-to-date, indicating a potential for a third consecutive year of double-digit gains [2] Analyst Insights - Brian Mulberry from Zacks Investment Management noted a rotation from large-cap growth to large-cap value, suggesting investors are adopting a more defensive posture ahead of next year [2] - A survey of nine major investment banks indicated a forecasted 10% gain in the S&P 500 over the next 12 months, with expectations that the index will surpass 7,500 by 2026 [3] Investment Methodology - The article identifies the top 14 S&P 500 stocks based on positive analyst sentiment and hedge fund interest, utilizing data from Insider Monkey's database as of Q3 2025 [5] - The strategy has historically outperformed the market, returning 427.7% since May 2014, significantly beating its benchmark [6] Company Highlights Thermo Fisher Scientific Inc. (NYSE:TMO) - Ranked 14th among the best S&P 500 stocks, with 121 hedge fund holders and a consensus Strong Buy rating [7] - Analysts have set a one-year average price target of $640.30, representing a 12% upside [7] - Wells Fargo raised its price target to $675 from $635, citing favorable U.S. government policies and growth projections [8] - Citigroup upgraded the stock to Buy from Neutral, increasing its price target to $660 from $580, driven by onshoring trends and increased pharmaceutical spending [9] - The stock has gained 8% year-to-date [10] Oracle Corporation (NYSE:ORCL) - Ranked 13th with 122 hedge fund holders and a consensus Moderate Buy rating [11] - Barclays maintains an Overweight rating with a price target of $310, while RBC Capital cut its target to $250 from $310 [11] - Oracle's diluted EPS of $2.26 exceeded estimates, but revenue and other key metrics fell short of expectations [12] - The company anticipates capital expenditures to be $15 billion higher than initially projected [13] - Future share price stability will depend on capital efficiency and free cash flow recovery [14] - Analysts have set a one-year average price target of $308.87, indicating a 67% upside [15]